Datametrex AI (CVE:DM) Hits New 52-Week Low - Time to Sell?

Datametrex AI Limited (CVE:DM) has reached a new low in its share price, hitting a 52-week low on Tuesday. The stock traded down to C$0.12 and eventually settled at C$0.11, with a trading volume of 53,008 shares. Previously, the stock had closed at C$0.12.

Datametrex AI Stock Performance

The stock is currently down 4.3%. Over the last 50 days, its moving average stands at C$0.02, while the two-hundred day moving average is at C$0.01. The company exhibits a significant debt-to-equity ratio of 554.49, a quick ratio of 2.44, and a current ratio of only 0.40. Presently, Datametrex AI has a market capitalization of C$66.44 million, a price-to-earnings ratio (PE) of -1.57, and a beta of 2.59, indicating higher volatility compared to the market.

Company Overview

Datametrex AI Limited is involved in collecting, analyzing, and presenting both structured and unstructured data through the use of machine learning and artificial intelligence, primarily in Canada and South Korea. The company operates within two main segments: AI and Technology and Health Care. Its health security offerings include concierge medical services and telemedicine. Additionally, the company provides services through Imagine Health, which features an integrated medical center, pharmacy, ancillary services, physician consultations, and sales of prescription and over-the-counter products.

Investment Considerations

Investors considering whether to buy or sell Datametrex AI may want to take note that MarketBeat has flagged several stocks that have received stronger recommendations from analysts. Currently, Datametrex AI holds a "Hold" rating among market analysts, but there are five other stocks that experts are suggesting as better options for investment at this time.

To shed light on current investment trends, MarketBeat is also tracking which stocks are attracting interest from institutional investors. If you want to stay informed about the market, you can sign up to receive updates on stocks favored by hedge funds and endowments.

This article is based on financial data and reports reviewed prior to publication. If interested, please reach out for more information.

Stocks, Market, Investment